IMUX Immunic Inc

Price (delayed)

$9.37

Market cap

$127.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.88

Enterprise value

-$26.92M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 ...

Highlights
The quick ratio has soared by 144% YoY and by 2.1% from the previous quarter
The EPS has decreased by 49% from the previous quarter but it has increased by 44% YoY
The company's debt has surged by 125% QoQ and by 60% YoY
Immunic's net income has decreased by 46% YoY and by 42% QoQ

Key stats

What are the main financial stats of IMUX

IMUX stock price

How has the Immunic stock price performed over time
Intraday
-13.56%
1 week
-7.41%
1 month
-43.21%
1 year
5.64%
YTD
75.47%
QTD
-39.04%

Financial performance

How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$117.88M
Net income
-$111.57M
Gross margin
N/A
Net margin
N/A
IMUX's operating income has dropped by 50% year-on-year and by 42% since the previous quarter
Immunic's net income has decreased by 46% YoY and by 42% QoQ

Price vs fundamentals

How does IMUX's price correlate with its fundamentals

Growth

What is Immunic's growth rate over time

Valuation

What is Immunic stock price valuation
P/E
N/A
P/B
1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 49% from the previous quarter but it has increased by 44% YoY
The price to book (P/B) is 45% lower than the 5-year quarterly average of 2.1
IMUX's equity is down by 16% since the previous quarter

Efficiency

How efficient is Immunic business performance
The company's return on equity has surged by 54% YoY and by 5% QoQ
The company's return on assets rose by 34% YoY but it fell by 8% QoQ

Dividends

What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMUX.

Financial health

How did Immunic financials performed over time
The total assets has soared by 159% year-on-year but it is down by 16% since the previous quarter
The quick ratio has soared by 144% YoY and by 2.1% from the previous quarter
The company's debt is 100% lower than its equity
The company's debt has surged by 125% QoQ and by 60% YoY
The company's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.